Hepatotoxicity Reduction Profiles of Antisense Oligonucleotides Containing Amido-Bridged Nucleic Acid and 2′-O,4′-C-Spirocyclopropylene Bridged Nucleic Acid
Nucleic Acid Therapeutics · 01.06.2025 · 35 (3) · 114-124
DOI: 10.1089/nat.2024.0047 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acid Therapeutics, online erschienen am 05.06.2025. Verfasst von Takaaki Kawanobe und 8 weiteren Autor:innen. Beteiligte Einrichtung: Luxna Biotech Co., Ltd., Suita, Osaka, Japan. Hauptthemen laut MEDLINE: Oligonucleotides, Antisense, Liver, Nucleic Acids, Spiro Compounds. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Amido-bridged nucleic acid (AmNA) and a 2′-O,4′-C-spirocyclopropylene bridged nucleic acid (scpBNA) are bridged nucleic acid analogs with high binding affinity toward complementary strands along with high nuclease resistance. AmNA and scpBNA have been developed to overcome phosphorothioate modified gapmer hepatotoxicity, while the mechanism of reducing hepatotoxicity still remains unknown. Here, we found that antisense oligonucleotides (ASOs) with combination of AmNA, scpBNA, and phosphodiester (PO) bonds could significantly reduce hepatotoxicity in mice. Histopathological findings of the periportal spaces of the liver were observed only in the locked nucleic acid and AmNA-scpBNA groups, but not in the AmNA-scpBNA-PO group. Furthermore, bioinformatics and histopathological analysis revealed that the reduced hepatotoxicity might be related to mitochondrial abnormalities, such as decreased expression levels of Atp5o and Sdhb genes. Taken together, the results of this study demonstrated that AmNA, scpBNA, and PO modification are able to reduce hepatotoxicity for improving the potential of ASOs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Luxna Biotech Co., Ltd., Suita, Osaka, Japan.
- Axcelead Drug Discovery Partners, Inc., Fujisawa, Kanagawa, Japan.
ORCID-Profile: Takaaki Kawanobe
Zitieren
APA
Kawanobe, T., Asano, S., Kandori, H., Aoki, M., Shrestha, A. R., Sekiguchi, K., Yokoyama, K., Fukuda, R., & Umemoto, T. (2025). Hepatotoxicity Reduction Profiles of Antisense Oligonucleotides Containing Amido-Bridged Nucleic Acid and 2′-O,4′-C-Spirocyclopropylene Bridged Nucleic Acid. Nucleic Acid Therapeutics, 35(3), 114-124. https://doi.org/10.1089/nat.2024.0047
Vancouver
Kawanobe T, Asano S, Kandori H, Aoki M, Shrestha AR, Sekiguchi K, et al. Hepatotoxicity Reduction Profiles of Antisense Oligonucleotides Containing Amido-Bridged Nucleic Acid and 2′-O,4′-C-Spirocyclopropylene Bridged Nucleic Acid. Nucleic Acid Therapeutics. 2025;35(3):114-124. doi:10.1089/nat.2024.0047
BibTeX
@article{Kawanobe2025,
author = {Kawanobe, Takaaki and Asano, Shinya and Kandori, Hitoshi and Aoki, Masami and Shrestha, Ajaya Ram and Sekiguchi, Kazuo and Yokoyama, Kotaro and Fukuda, Ryo and Umemoto, Tadashi},
title = {Hepatotoxicity Reduction Profiles of Antisense Oligonucleotides Containing Amido-Bridged Nucleic Acid and 2′-O,4′-C-Spirocyclopropylene Bridged Nucleic Acid},
journal = {Nucleic Acid Therapeutics},
year = {2025},
volume = {35},
number = {3},
pages = {114--124},
doi = {10.1089/nat.2024.0047}
}
EUVIMED